The latest biotech news

News and Trends 9 Feb 2023

New method to design new peptide therapeutics

Researchers at Hokkaido University in Japan have developed a novel method to design and develop peptide antibiotics in large numbers, which could prove critical to controlling antibiotic resistance. Applications of new molecules as drugs are expected to be effective in treating diseases that are difficult to cure with currently used conventional drugs. Peptides are one […]

February 9, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 9 Feb 2023

Cell and Gene Therapy Catapult boost for life science campus

The Cell and Gene Therapy Catapult (CGT Catapult), an independent U.K. innovation and technology organization specializing in the advancement of cell and gene therapies, has announced its involvement in the development of a major new campus for life science businesses in Stevenage. The new campus was announced by UBS Asset Management’s Real Estate & Private […]

February 9, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 9 Feb 2023

Icosagen receives €18M loan for R&D and new facility

The Estonian biopharma company Icosagen AS has reached an €18 million financing agreement with the European Investment Bank (EIB) backed by the InvestEU program. The funds will strengthen the company’s drug discovery, development and production services. The funds are part of Icosagen’s €40 million investment into increasing its innovative contract research and development capabilities as […]

February 9, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 9 Feb 2023

TILT Biotherapeutics closes €22M financing for oncology immunotherapy trials

TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies, has closed its €22 million ($23.8 million) round. This follows on from the first close of €10 million in June 2022. The financing was led by Finland’s Lifeline Ventures, an early-stage venture capital firm founded by serial entrepreneurs. The funding will be used to advance […]

February 9, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 9 Feb 2023

First toxic shock syndrome vaccine phase 2 study completed

The first vaccine to potentially prevent Staphylococcal-induced toxic shock syndrome (TSS) has successfully completed a phase 2 study. TSS is a life-threatening condition caused by toxins that can lead to multiple organ failure and death. Nosocomial pathogen methicillin-resistant Staphylococcus aureus (MRSA) bacteria are resistant to widely-used antibiotics. Infections with MRSA are harder to treat and […]

February 9, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 9 Feb 2023

Cleveland Clinic breast cancer vaccine study moves forward

Researchers from global health system Cleveland Clinic have launched the next step in their novel study of a vaccine aimed at preventing triple-negative breast cancer, the most aggressive and lethal form of the disease. Funded by the U.S. Department of Defense, the new phase 1b study will enroll cancer-free individuals at high risk for developing […]

February 9, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 7 Feb 2023

Antibody candidate for treating serious liver disease

There is currently no drug for treating non-alcoholic fatty liver disease, which affects many people with type 2 diabetes and which can result in other serious liver diseases. However, a new study led by researchers from Karolinska Institutet in Sweden has identified a drug candidate for the treatment of fatty liver. The preclinical study, published […]

February 7, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 7 Feb 2023

Evonetix closes $24M financing

Evonetix Ltd, a synthetic biology company bringing semiconductor technology to DNA synthesis, has completed a $24 million financing round, extending its total series B funding to over $54 million. This fundraise was led by existing investor Foresite Capital, with Molten Ventures, Morningside, DCVC, Cambridge Consultants, Civilization Ventures and Providence also participating in the round. The […]

February 7, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 7 Feb 2023

Harvard spin-off cellvie closes $5.5M new funding

cellvie Inc., which works on therapeutic mitochondria transplantation (TMT), an approach developed at Harvard Medical School, has closed a $5.5 million financing to get Series A-ready by the end of 2023. Mitochondria dysfunction has been tied to a host of diseases, ranging from neurodegenerative ailments, heart attacks and strokes, to age-related degeneration. “Whilst mitochondria have […]

February 7, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 7 Feb 2023

Mnemo Therapeutics and Institut Curie studies lead to cancer-specific targets

Mnemo Therapeutics, a French biotechnology company developing immunotherapies, has announced publication of two scientific studies developed at Institut Curie, its closest academic collaborator, in the journal Science Immunology. The publications reveal TE-exon splicing junctions act as a source of novel recurrent, cancer-specific targets and have potential implications for developing more effective and less toxic immunotherapies. […]

February 7, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 7 Feb 2023

Certa scleroderma study shows improvement in more than 60% of patients

Certa Therapeutics has announced what it says are ground-breaking clinical trial data for FT011, its novel therapy for the treatment of serious inflammatory and fibrotic diseases. Certa Therapeutics has recently completed a global phase 2, multi-centre, randomized, double blind, placebo-controlled study of the pharmacokinetics, pharmacodynamic effects, and safety, of oral FT011 in patients with scleroderma. […]

February 7, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 7 Feb 2023

AAHI bags $9.9M to develop nasal spray influenza RNA vaccine

The Access to Advanced Health Institute (AAHI) has been awarded a project agreement worth up to $9.9 million through the Medical CBRN Defense Consortium (MCDC) Other Transaction Authority (OTA) to develop a prototype intranasal bivalent influenza RNA vaccine candidate. The candidate will be based on AAHI’s self-amplifying RNA (saRNA) platform, which targets both pandemic A(H5N1) […]

February 7, 2023 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

New method to design new peptide therapeutics

Cell and Gene Therapy Catapult boost for life science campus

Icosagen receives €18M loan for R&D and new facility

TILT Biotherapeutics closes €22M financing for oncology immunotherapy trials

First toxic shock syndrome vaccine phase 2 study completed

Cleveland Clinic breast cancer vaccine study moves forward

Antibody candidate for treating serious liver disease

Evonetix closes $24M financing

Harvard spin-off cellvie closes $5.5M new funding

Mnemo Therapeutics and Institut Curie studies lead to cancer-specific targets

Certa scleroderma study shows improvement in more than 60% of patients

AAHI bags $9.9M to develop nasal spray influenza RNA vaccine

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!